Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2029

Conditions

Autoimmune Diseases

Interventions

DRUG

Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis

A single intravenous infusion of anti-CD19/BCMA CAR gene vector injection(dose-escalating infusion of 1.0-4.0 x10\^6 TU/kg）

Trial Locations (1)

RECRUITING

Anhui Provincial Hospital, Hefei

All Listed Sponsors

lead

Anhui Provincial Hospital

OTHER_GOV

NCT07121777 - Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases | Biotech Hunter | Biotech Hunter